Advancing precision oncology with spatial biomarkers: A novel multiplex imaging and AI-powered workflow

The promise of precision oncology lies in understanding not only what biomarkers are present in a tumor, but where they are—and how their spatial relationships influence treatment response. In a groundbreaking study, researchers used multiplex imaging and AI-driven spatial analysis to reveal, for the first time, how melanoma patients respond to immunotherapy, identifying predictive spatial biomarkers that correlate with outcomes.

This webinar will bring together experts in immuno-oncology, digital pathology, and clinical oncology to discuss how spatial biology and advanced image analysis are transforming cancer research and care. Speakers will highlight how a multiplex immunofluorescence workflow and deep-learning analysis enabled the identification of immune niches associated with therapeutic response, and how this approach could be expanded across cancer types.

By the end of this webinar, participants will:

• Understand how multiplex imaging and AI-powered spatial analysis can identify predictive biomarkers and the spatial features that inform treatment selection in melanoma and other cancers.
• Explore how spatial biology enhances translational research by revealing immune cell interactions that drive therapy response or resistance.
• Recognize how emerging analytical workflows can bridge discovery and clinical practice, accelerating the adoption of precision oncology worldwide.

Date & time:
Designed for a global audience of translational researchers and clinicians, the session will feature two live broadcasts with Q&A to accommodate participants across regions.

• Monday, Dec. 15th 2025,  8 AM CET, 3 PM CST/HKT/SGT, 4 PM JST/KST
• Monday, Dec. 15th 2025, 12 PM ET, 6 PMCET, 10:30 PM IST

Speakers:

	Paolo A. Ascierto, MD National Tumor Institute – Naples, Italy Paolo A. Ascierto is the director of the Department of Melanoma, Cancer Immunotherapy, and Development Therapeutics at the National Tumor Institute ofNaples, Italy. As of October, he is full professor of oncology at the University of Naples Federico II. He served as principal investigator in over 160 clinical trials and is an active member in several international medical societies. He is the author of around 750 publications with an impact factor of >8000 and H-index of 116.
	Ettai Markovits, PhD Nucleai – Tel Aviv, Israel Dr. Ettai Markovits is a medical professional and researcher. He earned his medical degrees with honors from the Hebrew University and conducted his Ph.D. at Tel Aviv University, focusing on immunotherapy response and resistance mechanisms in melanoma patients. Dr. Markovits serves as the director of biomedical research at Nucleai, leading efforts in cancer biomarker identification using spatial biology. His recent work focuses on developing novel analysis pipelines for multiplex imaging, harnessing deep profiling of the tumor microenvironment to improve biomarker discovery and enable precision medicine.
	Antonio Sorrentino, PhD Lunaphore – Tolochenaz, Switzerland Dr. Antonio Sorrentino is head of translational strategy at Lunaphore Technologies, leading translational and clinical strategy inception, planning, and execution, as well as clinical diagnostics market development. Dr. Sorrentino earned a M.Sc. in biomolecular sciences at Sapienza University of Rome and a Ph.D. in molecular pathology from the Catholic University Medical School in Rome. Dr. Sorrentino has 20 years of experience in the life sciences and diagnostics markets, and a long-standing focus on molecular oncology, translational medicine, and biomarker discovery and development. Prior to Lunaphore, he held senior roles at Exiqon, QIAGEN, and Labcorp Drug Development.